{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lupron&page=2",
    "query": {
      "intervention": "Lupron",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lupron&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T14:48:45.881Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01257802",
      "title": "GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic",
        "Systemic Vasculitis",
        "Isolated Angiitis of Central Nervous System",
        "Lung Disease With Systemic Sclerosis",
        "Lung Disease Interstitial Diffuse"
      ],
      "interventions": [
        {
          "name": "depot leuprolide acetate 3.75 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph Mccune",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 14,
      "start_date": "2011-05",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-27",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257802"
    },
    {
      "nct_id": "NCT05645536",
      "title": "Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TOL2506",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Letrozole tablets",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole Tablets",
          "type": "DRUG"
        },
        {
          "name": "Exemestane Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tolmar Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "ALL",
        "summary": "18 Years to 51 Years"
      },
      "enrollment_count": 250,
      "start_date": "2022-12-28",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 17,
      "location_summary": "Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05645536"
    },
    {
      "nct_id": "NCT06330805",
      "title": "Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage IIB Prostate Cancer AJCC v8",
        "Stage IIC Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Contrast Agent",
          "type": "OTHER"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Physical Performance Testing",
          "type": "OTHER"
        },
        {
          "name": "Relugolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 70,
      "start_date": "2024-08-12",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06330805"
    },
    {
      "nct_id": "NCT00203996",
      "title": "Polycystic Ovary Syndrome (PCOS) and Sleep Apnea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "continuous positive airway pressure (CPAP)",
          "type": "DEVICE"
        },
        {
          "name": "depot leuprolide plus estrogen/progestin replacement",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "REM frag",
          "type": "PROCEDURE"
        },
        {
          "name": "SWS supp",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 37,
      "start_date": "2003-09",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00203996"
    },
    {
      "nct_id": "NCT07142551",
      "title": "Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing hormone-releasing hormone (LHRH) analogue",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2026-03-09",
      "completion_date": "2034-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142551"
    },
    {
      "nct_id": "NCT04484818",
      "title": "Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Triptorelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2021-03-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 115,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 88 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484818"
    },
    {
      "nct_id": "NCT04557059",
      "title": "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "LHRHa",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Janssen Pharmaceutica N.V., Belgium",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 691,
      "start_date": "2020-11-12",
      "completion_date": "2031-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557059"
    },
    {
      "nct_id": "NCT00026377",
      "title": "SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "flutamide",
          "type": "DRUG"
        },
        {
          "name": "goserelin acetate",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "SU5416",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 3,
      "start_date": "2001-11",
      "completion_date": "2003-04",
      "has_results": false,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • LaGrange, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "LaGrange",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026377"
    },
    {
      "nct_id": "NCT04906395",
      "title": "Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TOL2506",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Letrozole Tablets",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole Tablets",
          "type": "DRUG"
        },
        {
          "name": "Exemestane Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tolmar Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 250,
      "start_date": "2021-07-01",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 17,
      "location_summary": "Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Parker",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Glenn Dale",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04906395"
    },
    {
      "nct_id": "NCT01120236",
      "title": "Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 211,
      "start_date": "2010-12",
      "completion_date": "2017-08-23",
      "has_results": true,
      "last_update_posted_date": "2018-02-26",
      "last_synced_at": "2026-09-15T14:48:45.881Z",
      "location_count": 169,
      "location_summary": "Fairbanks, Alaska • Little Rock, Arkansas • Rogers, Arkansas + 117 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01120236"
    }
  ]
}